Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alpha 1 Biomedicals

Executive Summary

Vincent Simmon, PhD, named president and CEO of the Washington, D.C.-based peptide R&D firm. He joins the company from W. R. Grace, where he served as VP-biotechnology research. Earlier, Simmon held a number of executive positions with Genex Corp., including VP-R&D. Two of Simmon's immediate priorities at Alpha 1 Biomedicals will be the commercialization of Thymosin Alpha 1 and an AIDS vaccine product, HGP-30, based on the p17 core antigen. The latter, which is about to begin human testing in the state of California, is being developed via a joint venture with Cel-Sci.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017182

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel